|
Theravance Reports Third Quarter 2010 Financial Results
MarketWatch (press release) "The RELOVAIR(TM) Phase 3 programs in COPD and asthma are progressing well and have now enrolled over 8000 patients. Last month, preclinical and Phase 2a … |
View full post on asthma – Google News